Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Shares of WW International, formerly WeightWatchers ( NASDAQ: WW ), jumped on Tuesday after it announced a partnership with ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...